- Visby Medical is a leader in rapid at-home PCR diagnostics, recently recognized for launching the first FDA-authorized at-home PCR STI test for women.
- In June 2025, Visby Medical raised up to $65 million in funding led by Catalio Capital Management to accelerate the commercial launch of its at-home Women's Sexual Health Test, set to be available in July 2025.
- The company has partnered with Wisp, the largest pure play women’s telehealth company in the U.S., to expand access to its at-home STI testing solutions.
- Visby Medical's ideal buyers include healthcare providers and telehealth companies looking to enhance patient care by offering quick, lab-accurate STI testing that addresses the critical need for accessible sexual health diagnostics.
Engineering is the largest function at Visby Medical with 42 employees, underscoring the firm’s emphasis on product development and test automation. Sales and Support follows with 20 employees who focus on customer adoption and technical assistance. Core business operations are spread across Operations (17 employees), Business Management (14), Marketing and Product (12), and Finance and Administration (12). Human Resources, Healthcare specialists, Information Technology, and a small group classified as Other account for the remaining roles, creating a diversified yet product-centric organizational structure.
Visby Medical’s workforce is concentrated in California. San Jose hosts the biggest group with 41 employees, while 33 employees work out of San Francisco. Additional clusters are located in Sunnyvale, Santa Clara, Cupertino, and San Diego, each ranging from three to four employees. Outside California, small teams operate in Denver, Salt Lake City, and Israel. An “Other” category represents 57 remote or satellite staff, highlighting a hybrid approach that combines centralized engineering hubs with distributed talent across multiple regions.
